These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27508895)

  • 1. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
    Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH
    J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly Developed Dopamine D
    Jordan CJ; Humburg BA; Thorndike EB; Shaik AB; Xi ZX; Baumann MH; Newman AH; Schindler CW
    J Pharmacol Exp Ther; 2019 Dec; 371(3):602-614. PubMed ID: 31562201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats.
    You ZB; Gao JT; Bi GH; He Y; Boateng C; Cao J; Gardner EL; Newman AH; Xi ZX
    Neuropharmacology; 2017 Nov; 126():190-199. PubMed ID: 28888944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The highly selective dopamine D
    Jordan CJ; Humburg B; Rice M; Bi GH; You ZB; Shaik AB; Cao J; Bonifazi A; Gadiano A; Rais R; Slusher B; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107597. PubMed ID: 30974107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.
    Boateng CA; Bakare OM; Zhan J; Banala AK; Burzynski C; Pommier E; Keck TM; Donthamsetti P; Javitch JA; Rais R; Slusher BS; Xi ZX; Newman AH
    J Med Chem; 2015 Aug; 58(15):6195-213. PubMed ID: 26203768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D
    Shaik AB; Kumar V; Bonifazi A; Guerrero AM; Cemaj SL; Gadiano A; Lam J; Xi ZX; Rais R; Slusher BS; Newman AH
    J Med Chem; 2019 Oct; 62(20):9061-9077. PubMed ID: 31526003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D
    Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH
    J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the selective dopamine D
    Botz-Zapp CA; Foster SL; Pulley DM; Hempel B; Bi GH; Xi ZX; Newman AH; Weinshenker D; Manvich DF
    Behav Brain Res; 2021 Oct; 415():113506. PubMed ID: 34352292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.
    Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC
    Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Dual-Target μ-Opioid Receptor and Dopamine D
    Bonifazi A; Battiti FO; Sanchez J; Zaidi SA; Bow E; Makarova M; Cao J; Shaik AB; Sulima A; Rice KC; Katritch V; Canals M; Lane JR; Newman AH
    J Med Chem; 2021 Jun; 64(11):7778-7808. PubMed ID: 34011153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Perspectives on Selective Dopamine D
    Newman AH; Xi ZX; Heidbreder C
    Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
    Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
    Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice.
    Le Foll B; Francès H; Diaz J; Schwartz JC; Sokoloff P
    Eur J Neurosci; 2002 Jun; 15(12):2016-26. PubMed ID: 12099907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.
    Cheung TH; Loriaux AL; Weber SM; Chandler KN; Lenz JD; Schaan RF; Mach RH; Luedtke RR; Neisewander JL
    J Pharmacol Exp Ther; 2013 Nov; 347(2):410-23. PubMed ID: 24018640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.
    McNamara RK; Levant B; Taylor B; Ahlbrand R; Liu Y; Sullivan JR; Stanford K; Richtand NM
    Neuroscience; 2006 Nov; 143(1):141-53. PubMed ID: 16938406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly D
    Galaj E; Bi GH; Klein B; Hempel B; Shaik AB; Gogarnoiu ES; Friedman J; Lam J; Rais R; Reed JF; Bloom SH; Swanson TL; Schmachtenberg JL; Eshleman AJ; Janowsky A; Xi ZX; Newman AH
    Neuropsychopharmacology; 2022 Dec; 47(13):2309-2318. PubMed ID: 35879349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
    Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
    Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.
    Lv Y; Hu RR; Jing M; Zhao TY; Wu N; Song R; Li J; Hu G
    Acta Pharmacol Sin; 2019 May; 40(5):583-588. PubMed ID: 30224637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.